Response: Re: Cost-effectiveness analysis of human papillomavirus vaccination in the Netherlands.
Mark Hermannes
MH
Rozenbaum
Cornelis
C
Boersma
D052685:Alphapapillomavirus / Q000276:immunology*; D003362:Cost-Benefit Analysis; D016527:Drug Costs; D005260:Female; D006801:Humans; D009426:Netherlands; D030361:Papillomavirus Infections / Q000191:economics / Q000517:prevention & control*; D053918:Papillomavirus Vaccines / Q000008:administration & dosage / Q000191:economics*; D019057:Quality-Adjusted Life Years; D014412:Tumor Virus Infections / Q000191:economics / Q000517:prevention & control*
D053918:Papillomavirus Vaccines